Post by icemandios on Aug 8, 2023 12:31:41 GMT
Xeris Biopharma Reports Second Quarter 2023 Financial Results
Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year
Ended Q2 with over $80M in cash, cash equivalents and short-term investments
Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utilization of $57M-$67M; 2023 year-end cash balance of $55M-$65M
Remains on track to achieve cash flow breakeven by year-end 2023
Hosting conference call and webcast today at 8:30 a.m. ET
Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year
Ended Q2 with over $80M in cash, cash equivalents and short-term investments
Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utilization of $57M-$67M; 2023 year-end cash balance of $55M-$65M
Remains on track to achieve cash flow breakeven by year-end 2023
Hosting conference call and webcast today at 8:30 a.m. ET